TP53 and myelodysplastic syndrome: The second drug with potential clinical activity in TP53-mutant MDS is magrolimab, a first-in-class anti-CD47 antibody, which synergizes with AZA and induce “eat me” signals on leukemic stem cells by restoring macrophage-mediated phagocytosis [108].